SWOG clinical trial number
S0032

Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate

Closed
Phase
Accrual
48%
Published
Abbreviated Title
Advanced Prostate
Activated
12/01/2001
Closed
06/01/2005
Participants
NCORP, Members, UCOP, Medical Oncologists, Surgeons

Research committees

Genitourinary Cancer

Treatment

Paclitaxel Bicalutamide Estramustine Etoposide Flutamide Leuprolide Acetate Goserelin Acetate Surgery Nilutamide

Eligibility Criteria Expand/Collapse

Histologically or cytologically proven dx of adenoca of the prostate; clinical Stage D2 (soft tissue or bony mets) as specified; < 30 days of androgen suppression; prestudy PSA; PS 0-2; prior RT, biologic tx, surgery allowed; no prior chemo; no brain mets; no active thrombophlebitis or hypercoagulability; no PE; no TIA, stroke or MI w/in 6 mo.; no active coronary artery disease; pt should be offered participation in SWOG-9205 and tissue banking.

Publication Information Expand/Collapse

2016

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials

D Hershman;C Till;J Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology Sep 1;34(25):3014-3022; 2016 Jun 20 [Epub ahead of print]

PMid: PMID27325863 | PMC number: PMC5012713

Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials

DL Hershman;C Till;JD Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology 34, 2016 (suppl; abstr 10001); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation

2011

Phase II evaluation of early oral estramustine, oral etoposide and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group (SWOG) S0032 [PMID21334731]

DC Smith;CM Tangen;G Harrer;PJ Van Veldhuizen;G Harrer;A Golshayan;G Mills;N Vogelzang;IM Thompson;MHA Hussain Urology 77(5):1172-1176; Epub 2011 Feb 21;

2009

Cooperative group trials - Southwest Oncology Group (SWOG) innovations in advanced prostate cancer [PMID21085622; PMC2981166]

TB Dorff;C Tangen;ED Crawford;DP Petrylak;CS Higano;D Raghavan;DI Quinn;NJ Vogelzang;IM Thompson;MHA Hussain Therapeutic Advances in Medical Oncology 1(2):69-77;

Other Clinical Trials

SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase